These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18690503)

  • 1. Natalizumab: a country-based surveillance program.
    Mancardi GL; Amato MP; D'Alessandro R; Drago F; Milanese C; Popoli P; Provinciali L; Rossi P; Savettieri G; Tedeschi G; Tola MR; Vanacore N; Covezzoli A; De Rosa M; Piccinni C; Montanaro N; Periotto L; Addis A; Martini N
    Neurol Sci; 2008 Sep; 29 Suppl 2():S235-7. PubMed ID: 18690503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacovigilance program on natalizumab in Italy: 2 years of experience.
    Tedeschi G; Amato MP; D'Alessandro R; Drago F; Milanese C; Popoli P; Rossi P; Savettieri G; Tola MR; Vanacore N; Covezzoli A; De Rosa M; Comi G; Pozzilli C; Bertolotto A; Marrosu MG; Grimaldi LM; Piccinni C; Montanaro N; Periotto L; Iommelli R; Addis A; Martini N; Provinciali L; Mancardi GL
    Neurol Sci; 2009 Oct; 30 Suppl 2():S163-5. PubMed ID: 19882367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrocephalus during natalizumab treatment.
    Zecca C; Städler C; Gobbi C
    Neurol Sci; 2010 Oct; 31(5):635-7. PubMed ID: 20454819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.
    Stüve O; Cravens PD; Frohman EM; Phillips JT; Remington GM; von Geldern G; Cepok S; Singh MP; Tervaert JW; De Baets M; MacManus D; Miller DH; Radü EW; Cameron EM; Monson NL; Zhang S; Kim R; Hemmer B; Racke MK
    Neurology; 2009 Feb; 72(5):396-401. PubMed ID: 18987352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
    van Pesch V; Bartholomé E; Bissay V; Bouquiaux O; Bureau M; Caekebeke J; Debruyne J; Declercq I; Decoo D; Denayer P; De Smet E; D'hooghe M; Dubois B; Dupuis M; Sankari SE; Geens K; Guillaume D; van Landegem W; Lysandropoulos A; de Noordhout AM; Medaer R; Melin A; Peeters K; Ba RP; Retif C; Seeldrayers P; Symons A; Urbain E; Vanderdonckt P; Van Ingelghem E; Vanopdenbosch L; Vanroose E; Van Wijmeersch B; Willekens B; Willems C; Sindic C
    Acta Neurol Belg; 2014 Sep; 114(3):167-78. PubMed ID: 24915752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab: overview of its pharmacology and safety.
    Baker DE
    Rev Gastroenterol Disord; 2007; 7(1):38-46. PubMed ID: 17392628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.
    Giacoppo S; Ruscica M; Grimaldi LM; Bramanti P; Mazzon E
    Med Sci Monit; 2017 Sep; 23():4230-4240. PubMed ID: 28864818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies.
    Gold R; Jawad A; Miller DH; Henderson DC; Fassas A; Fierz W; Hartung HP
    J Neuroimmunol; 2007 Jul; 187(1-2):156-8. PubMed ID: 17499366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three years of experience: the Italian registry and safety data update.
    Mancardi GL; Tedeschi G; Amato MP; D'Alessandro R; Drago F; Milanese C; Popoli P; Rossi P; Savettieri G; Tola MR; Comi G; Pozzilli C; Bertolotto A; Marrosu MG; Grimaldi LM; Laroni A; Vanacore N; Covezzoli A; De Rosa M; Piccinni C; Montanaro N; Periotto L; Iommelli R; Tomino C; Provinciali L
    Neurol Sci; 2011 Jan; 31 Suppl 3():295-7. PubMed ID: 20644975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current treatment of multiple sclerosis].
    Gout O; Bensa C; Assouad R
    Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The toronto observational study of natalizumab in multiple sclerosis.
    Krysko KM; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):422-8. PubMed ID: 21515500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
    Klawiter EC; Cross AH; Naismith RT
    Neurology; 2009 Sep; 73(12):984-90. PubMed ID: 19770475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies in treatment of multiple sclerosis.
    Rommer PS; Dudesek A; Stüve O; Zettl UK
    Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.